The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the non-small cell lung cancer (nsclc) market?
The increasing rate of tobacco consumption is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. Tobacco consumption refers to the use of tobacco products by individuals, typically in the form of smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains several carcinogens that can damage the DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small-cell lung cancer (NSCLC). For instance, in October 2024, according to the 2024 National Youth Tobacco Survey published by US Food and Drug Administration (USFDA), a US-based federal agency, 1.1% of all students (approximately 2.25 million) reported current use of tobacco products, with 10.1% of high school students (about 1.58 million) and 5.4% of middle school students (around 640,000) using tobacco; additionally, 2.8% of students (about 760,000) reported current use of any combustible tobacco product, while 3.0% (approximately 840,000) reported using multiple tobacco products. Therefore, the increasing rate of tobacco consumption is driving the growth of the non-small cell lung cancer (NSCLC) market.
Non-Small Cell Lung Cancer (NSCLC) Market Driver: Rising Air Pollution Levels Linked To Increased Non-Small Cell Lung Cancer (Nsclc) Cases
Increasing air pollution is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. Air pollution refers to harmful substances, often in the form of gases or particles, in the Earth’s atmosphere that can adversely affect human health. Air pollution can increase the risk of non-small cell lung cancer by causing inflammation, DNA damage, and mutations in lung cells, leading to cancerous tumors. For instance, in June 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, air and household air pollution was associated with 7 million premature deaths annually. Additionally, around 2.4 billion people are exposed to dangerous levels of household air pollution while using polluting open fires for cooking fueled by kerosene, biomass, and coal. Furthermore, in September 2022, according to the World Bank, a US-based financial institution, the health damage caused by air pollution will amount to $8.1 trillion a year, equivalent to 6.1% of global GDP. Therefore, increasing air pollution is expected to propel the growth of the non-small cell lung cancer (NSCLC) market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
How has the non-small cell lung cancer (nsclc) market size evolved, and what are the latest forecasts for its expansion?
The non-small cell lung cancer (NSCLC) market size has grown rapidly in recent years. It will grow from $20.1 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to evolution of immunotherapy, genomic profiling and precision medicine, expansion of clinical trials, smoking cessation initiatives.
The non-small cell lung cancer (NSCLC) market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to emerging combination therapies, integration of artificial intelligence (AI), expansion of personalized vaccines, global collaborations in research, patient-centric care. Major trends in the forecast period include integration of telemedicine in oncology, liquid biopsy technologies, advances in diagnostic technologies, adoption of minimally invasive surgical techniques, immune checkpoint inhibitors.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
Which major companies dominate the non-small cell lung cancer (nsclc) market?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
What trends will shape the future of the non-injectable insulin market?
Major Companies operating in the non-small cell lung cancer (NSCLC) market are focused on developing multiple treatment options, such as monotherapy treatments, to gain a competitive edge. Monotherapy treatment is the use of a single drug or therapy to treat a medical disorder or condition, and it involves utilizing a single method or treatment approach rather than a combination of multiple interventions. For instance, in June 2022, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European Commission (EC), a Belgium-based governing body, for Tabrecta (capmatinib) for the treatment of adult patients with advanced non-small cell lung cancer with METex14 skipping. It offers a novel targeted therapeutic option for patients in Europe who have received prior treatment and have advanced non-small cell lung cancer (NSCLC) that has mutations that cause MET exon 14 (METex14) skipping. It is the most popular targeted treatment for advanced NSCLC and has modifications that cause METex14 skipping.
Which region dominates the non-small cell lung cancer (nsclc) market, and what factors contribute to its leadership?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
How is the non-small cell lung cancer (nsclc) market segmented, and which segment holds the largest share?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented –
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232
What defines the structure and scope of the non-small cell lung cancer (nsclc) market?
Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
